Government in the Sunshine Act Meeting Notice, 14913 [2017-05893]
Download as PDF
<![CDATA[
14913
Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices
INTERNATIONAL TRADE
COMMISSION
[USITC SE–17–012]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: March 30, 2017 at 11:00
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
AGENCY HOLDING THE MEETING:
Matters To Be Considered
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. No. 731–TA–1314
(Final) (Phosphor Copper from Korea).
The Commission is currently scheduled
to complete and file its determination
and views of the Commission by April
17, 2017.
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: March 21, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–05893 Filed 3–21–17; 4:15 pm]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as bulk
manufacturers of various classes of
controlled substances.
SUPPLEMENTARY INFORMATION:
The companies listed below applied
to be registered as manufacturers of
various basic classes of controlled
substances. Information on previously
published notices is listed in the table
below. No comments or objections were
submitted for these notices.
SUMMARY:
Company
FR docket
sradovich on DSK3GMQ082PROD with NOTICES
Noramco, Inc .................................................................................................................................................
Isosciences ....................................................................................................................................................
AMRI Rensselaer, Inc ...................................................................................................................................
Halo Pharmaceutical, Inc ..............................................................................................................................
AMPAC Fine Chemicals LLC ........................................................................................................................
Insys Manufacturing LLC ..............................................................................................................................
Patheon API Manufacturing, Inc ...................................................................................................................
Euticals Inc ....................................................................................................................................................
Nanosyn, Inc .................................................................................................................................................
Cerilliant Corporation .....................................................................................................................................
Research Triangle Institute ...........................................................................................................................
Synthcon LLC ................................................................................................................................................
Navinta LLC ...................................................................................................................................................
Johnson Matthey, Inc ....................................................................................................................................
AMRI Rensselaer, Inc ...................................................................................................................................
Cayman Chemical Company ........................................................................................................................
Cambridge Isotope Laboratories ...................................................................................................................
Janssen Pharmaceutical, Inc ........................................................................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of these registrants to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each of the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
VerDate Sep<11>2014
17:13 Mar 22, 2017
Jkt 241001
Notice of registration.
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed persons.
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
57936
61249
61250
63220
63222
63221
64509
64510
64949
66079
91948
95641
95640
95647
95639
95644
95644
96045
Published
August 24, 2016.
September 6, 2016.
September 6, 2016.
September 14, 2016.
September 14, 2016.
September 14, 2016.
September 20, 2016.
September 20, 2016.
September 21, 2016.
September 26, 2016.
December 19, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 29, 2016.
Dated: March 17, 2017.
Louis J. Milione,
Assistant Administrator.
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
[FR Doc. 2017–05727 Filed 3–22–17; 8:45 am]
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
PO 00000
SUMMARY:
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
Notice of registration.
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 82, Number 55 (Thursday, March 23, 2017)]
[Notices]
[Page 14913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05893]
[[Page 14913]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[USITC SE-17-012]
Government in the Sunshine Act Meeting Notice
Agency Holding the Meeting: United States International Trade
Commission.
Time and Date: March 30, 2017 at 11:00 a.m.
Place: Room 101, 500 E Street SW., Washington, DC 20436, Telephone:
(202) 205-2000.
Status: Open to the public.
Matters To Be Considered
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. No. 731-TA-1314 (Final) (Phosphor Copper from
Korea). The Commission is currently scheduled to complete and file its
determination and views of the Commission by April 17, 2017.
5. Outstanding action jackets: None.
In accordance with Commission policy, subject matter listed above,
not disposed of at the scheduled meeting, may be carried over to the
agenda of the following meeting.
By order of the Commission.
Issued: March 21, 2017.
William R. Bishop,
Supervisory Hearings and Information Officer.
[FR Doc. 2017-05893 Filed 3-21-17; 4:15 pm]
BILLING CODE 7020-02-P
